Could cutting bladder pills boost brain health in Parkinson's?

NCT ID NCT07627529

Not yet recruiting Knowledge-focused Sponsor: Corporal Michael J. Crescenz VA Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether slowly reducing or stopping a type of bladder medication (antimuscarinics) can improve thinking and quality of life in people with Parkinson's disease. Twenty participants will go through periods of taking their usual dose and periods of tapering off, while their cognitive function and symptoms are tracked. The goal is to see if deprescribing these drugs is beneficial and feasible.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: overactive bladder antimuscarinic medication (deprescribing)
What this could lead to: If successful, this could show that reducing or stopping certain bladder medications may improve thinking and quality of life for people with Parkinson's disease.
What could go wrong: This is a very small, early-stage trial with only 20 participants. Results may not apply to everyone, and some people may experience worse bladder symptoms when reducing the medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

overactive bladder Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE (PD)

Contacts and locations

Locations

Corporal Michael J. Crescenz VA Medical Center

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.